Academic Publication Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances
Research Abstract & Technology Focus
Correlated Market Trend: Delivery Driver
Bridging academia to market: The 60-day public search velocity mapping directly to the core technology of this paper. Dashed line represents 7-day moving average.
AI Semantic Synergy Context
Connecting this academic literature to real-world market discussions and products.
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
AbstractThe glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and is found primarily on the surfaces of various cell ty...
Modulating nuclear stiffness and envelope barrier facilitates AAV nuclear entry and reduces immunogenicity
Low efficiency and immunotoxicity limit rAAVs clinical use. Here, the authors show that encapsulating rapamycin in PF127 micelles modulates cellular biomechanics, enhancing AAV-mediated gene transf...
Peptide-based drug discovery through artificial intelligence: towards an autonomous design of therapeutic peptides
Abstract With their diverse biological activities, peptides are promising candidates for therapeutic applications, showing antimicrobial, antitumour and hormonal signalling capabilit...
Enhancing Drug Solubility, Bioavailability, and Targeted Therapeutic Applications through Magnetic Nanoparticles
Biological variability poses significant challenges in the development of effective therapeutics, particularly when it comes to drug solubility and bioavailability. Poor solubility across varying p...
Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials
PURPOSE To evaluate the efficacy and safety of disitamab vedotin (DV, RC48-ADC), a novel humanized anti–human epidermal growth factor receptor 2 (HER2) antibody conjugated with monomethyl auristati...
Frequently Asked Questions (FAQ)
Curated market intelligence mapped to this research.
What is the core focus of the research titled 'Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances'?
This literature focuses on: Peptide and protein (PP) therapeutics are highly specific and potent biomolecules that treat chronic and complex diseases. However, their oral delivery is significantly hindered by enzymatic degradation, instability, and poor permeability through ...
What other academic literature is closely related to 'Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances'?
Yes, highly correlated activity was mapped. An entry titled 'Glucagon-like peptide-1 receptor: mechanisms and advances in therapy' discusses this: AbstractThe glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and is ...
Are there commercial applications of 'Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances' in market news publications?
Yes, highly correlated activity was mapped. An entry titled 'Modulating nuclear stiffness and envelope barrier facilitates AAV nuclear entry and reduces immunogenicity' discusses this: Low efficiency and immunotoxicity limit rAAVs clinical use. Here, the authors show that encapsulating rapamycin in PF127 micelles modulates cellula...
Cite this Market Intelligence Report
Reference our AI-mapped synergy between this research and the commercial market to instantly build authority.
SaaS Metrics